Navigation Links
GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
Date:12/1/2008

than 50% of the components of the AIDS virus (HIV-1) but cannot cause AIDS. GeoVax AIDS vaccines are designed to prevent HIV-1 virus infection which causes Acquired Immunodeficiency Disease (AIDS).

The Seattle meeting also achieved further progress with GeoVax's therapeutic trial. Information on this and other developments will be reported in a timely fashion in the near future.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment of people already infected with the HIV-1 virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.

GeoVax's core AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 /PRNewswire/ ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... shares of its common stock and Series C ... stock.  Funds under the management of QVT Financial ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... , December 24, 2014 ... Report on Global Disposable Syringe Industry of ... its online business intelligence library. ... Disposable Syringe Industry is a professional and ... market.  For overview analysis, the report introduces ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... RenalGuard To Be PresentedFRANKLIN, Mass., May 15 ... company focused on innovative cardiac and vascular medical ... its RenalGuard System(TM) at EuroPCR, the annual meeting ... (EAPCI), May 19-22, 2009, in Barcelona, Spain. ...
... an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, ... EGFR Activating Mutations - (1,2)-The First Presentation of Data ... Boehringer Ingelheim will present new data on the ... 1120 at the 2009 Annual Meeting of the American ...
Cached Medicine Technology:PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 2PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , , , ... has announced the promotion of Mark Gastineau to senior vice ... Small Group, and Government Business Unit (ISGBU). Gastineau joined ... and Underwriting, leading the finance, underwriting and compliance areas in ...
... chronic cholestatic inflammatory liver disease characterized by diffuse fibrosing ... bile duct obliteration, biliary cirrhosis, and eventually hepatic failure. ... of presentation of PSC is mild to severe abdominal ... mechanisms responsible for the abdominal pain in PSC are ...
... recognized to result in fragile bones with increased risk ... has varied from 11% to 48%, with a fracture ... poorly understood. With liver transplantation becoming a viable option ... survival, bone disease is becoming the major determinant of ...
... with early-stage malignancy, study shows , MONDAY, Aug. 10 ... of a young woman with early-stage ovarian cancer can ... study has found. , Researchers at Columbia University ... during the first five years following the cancer diagnosis ...
... , MONDAY, Aug. 10 (HealthDay News) -- According to ... toddler with a snout and tail. , "Dogs basically ... said dog expert Stanley Coren, who was scheduled to ... Association annual meeting this week in Toronto. , The ...
... , NEW YORK, Aug. 10 Rx for ... to form ZiRx Therapeutics, Ltd., a joint venture that will utilize the ... drugs that potentially block or stop the spread of infectious diseases in ... antiviral drugs as well as drugs that are less susceptible to viral ...
Cached Medicine News:Health News:Mark Gastineau Named Senior Vice President of Individual, Small Group, and Government Business Unit at Blue Shield of California 2Health News:Gallbladder emptying in primary sclerosing cholangitis patients 2Health News:Fertility Can Be Preserved in Ovarian Cancer Patients 2Health News:Dogs and 2-Year-Olds on Same Mental Plane 2Health News:Dogs and 2-Year-Olds on Same Mental Plane 3Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 2Health News:Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd. 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: